After being placed into FDA Category 2 in 2023, several widely discussed peptides faced restricted pathways for regulated compounding. This shift pushed demand toward unregulated markets and created significant uncertainty across the Peptides in 2026, What the FDA Review Means Olympia Pharmaceuticals Are Peptides coming off of the FDA Category 2 list? A legal breakdown. RFK Jr. & claimed regenerative peptides like BPC 157 The Niche FDA takes first step in possible reversal of ban on some peptides The Washington Post